In 2021, the profit of the special equipment industry will increase by more than 10%. How will the company perform?

[ Hot attention of chemical machinery and equipment network ] According to data released by the National Bureau of Statistics on January 27, in 2021, the profits of the equipment manufacturing industry in the middle and lower reaches will increase by 16.
3% over the previous year, and the average growth rate for the two years will be 13.
5%
.
Among them, nearly 90% of the equipment manufacturing industry profits increased over the previous year
.
Among the subdivided industries, the industries with high profit growth include electronics and metal products, which increased by 38.
9% and 28.
7% respectively
.
In addition, the profits of electrical machinery and special equipment industries increased by 12.
2% and 10.
2% respectively
.

 

　　Pharmaceutical equipment is a variety of machinery and equipment for pharmaceutical production enterprises, mainly including pharmaceutical-specific equipment and other non-pharmaceutical-specific equipment
.
So, with the profit growth of the special equipment industry exceeding 10% in 2021, how will the pharmaceutical special equipment industry perform?
  

　　Judging from the pharmaceutical machine companies that have disclosed their 2021 performance forecasts, Chutian Technology, Tofflon, Xinhua Medical, Canaan Technology, Huasheng Co.
, Ltd.
, Tailin Bio, Chengyitong, and Aoxing Life Technology have 8 pharmaceutical machine companies.
The company has disclosed the performance forecast, and the eight companies are expected to achieve a total net profit of 1.
746 billion yuan to 2.
032 billion yuan in 2021, an average year-on-year increase of over 125.
6%
.
On the whole, the overall performance of the pharmaceutical special equipment industry is better
.

 

　　It is worth mentioning that at present, the overall concentration of China's pharmaceutical equipment industry is not high, and the enterprises are mostly small and medium-sized
.
Among the 8 pharmaceutical machine companies with promising results, there are still a few companies whose net profit is expected to exceed 100 million yuan.
Only three companies, Aoxing Life Technology, Tofflon, Canaan Technology, and Chutian Technology, have achieved a scale of more than 100 million yuan, respectively.
The median net profit is about 834 million yuan, 550 million yuan, and 270 million yuan
.

 

　　Judging from the reasons for the pre-increase in performance, the high prosperity of the downstream biopharmaceutical industry has a strong pull on the profit growth of pharmaceutical machine companies
.
For example, Chutian Technology, which is expected to double its net profit in 2021, mentioned in its performance change statement that during the reporting period, the company focused on the development of biopharmaceutical equipment, and has basically completed the layout of biopharmaceutical front-end equipment, and has been in the high-end market and import substitution.
Great achievements have been made in the aspect; Tofflon also stated in the 2021 performance forecast report that during the reporting period, the company's biological macromolecules, cell equipment and other sectors have grown rapidly
.
In 2021, Tofflon's net profit will increase by 65%-95% over the same period of the previous year
.

 

　　It is understood that due to the resonance of policies, capital, talents and other factors, China's biopharmaceutical industry has grown rapidly in recent years.
In 2021, China's biopharmaceutical market will reach approximately 424.
8 billion yuan.
It is estimated that by 2024, China's biopharmaceutical market will exceed 100 billion yuan.
dollars
.

 

　　With the promising market prospects of the biopharmaceutical industry, the upstream biopharmaceutical equipment-related industries have also ushered in new opportunities.
On the one hand, the demand for high-end equipment has increased, and on the other hand, the pace of import substitution has accelerated
.
The blue ocean has emerged, and many pharmaceutical machine giants will continue to make arrangements in 2021
.

 

　　For example, Chutian Technology stated in the research activity information disclosed in 2021 that it will take heavy investment and major development in biological drug-related products, and plans to increase the annual sales growth rate of biological drug-related process technologies and process equipment to exceed other product lines , Competing with Sartorius in the biological field, complementing related product series and industrial chains
.
In the second half of 2021, Chutian Technology also established its holding subsidiaries, Chutian Siyoute and Chutian Microspheres, to further supplement the biopharmaceutical-related equipment and product chain; Tofflon once mentioned in the research activities that the development of biopharmaceuticals The preparation of stock solution and the output of engineering capabilities will be the track for the rapid growth of the market demand for innovative drugs in China and even the world in the future.
The company plans to form a team to meet the needs of domestic and foreign markets
.
In addition, Canaan Technology has also disclosed that the company plans to focus on developing the pharmaceutical liquid dispensing system, intelligent logistics system and pharmaceutical R&D service fields of bio-innovative drugs.
It believes that the rapid development of the bio-pharmaceutical industry will bring more business opportunities to the company.

.

 

　　Looking forward to 2022, with the in-depth development of major pharmaceutical machine companies in the field of biological drugs, combined with the still booming biopharmaceutical industry, the industry expects that the biological drug business of related pharmaceutical machine companies may continue to grow this year
.

 

　　Original title: In 2021, the profit of the special equipment industry will increase by more than 10%.
How is the performance of the pharmaceutical machinery industry?